Ileal bypass for hyperlipidemia

Henry Buchwald; Laurie Fitch; Richard L. Varco

doi:10.1007/BF01655389

Ileal bypass for hyperlipidemia

Henry Buchwald, Laurie Fitch, Richard L. Varco

Surgery

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Partial ileal bypass (PIB) is a safe, effective, and lasting therapy for the reduction of lipids and lipoproteins in patients with hyperlipidemia. Following PIB, circulating plasma and low-density lipoprotein (LDL) cholesterol fall markedly, while high-density lipoprotein (HDL) cholesterol rises. The average plasma cholesterol lowering is 25% after diet, with a 40% reduction in the LDL-cholesterol fraction; concurrently, the HDL-cholesterol rises about 8%. These effects have been demonstrated to be maintained for up to 20 years. Currently, PIB is being used in the Program on the Surgical Control of the Hyperlipidemias (POSCH), a randomized controlled clinical trial designed to assess the effects of lipid reduction on mortality and morbidity in a postmyocardial infarction population with arteriographically demonstrated coronary atherosclerosis.

Original language	English (US)
Pages (from-to)	850-859
Number of pages	10
Journal	World Journal of Surgery
Volume	9
Issue number	6
DOIs	https://doi.org/10.1007/BF01655389
State	Published - Dec 1985

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1007/BF01655389

OpenUrl availability

Full text

Cite this

@article{ec18107e9fce48a88c32c74c6a7b3202,

title = "Ileal bypass for hyperlipidemia",

abstract = "Partial ileal bypass (PIB) is a safe, effective, and lasting therapy for the reduction of lipids and lipoproteins in patients with hyperlipidemia. Following PIB, circulating plasma and low-density lipoprotein (LDL) cholesterol fall markedly, while high-density lipoprotein (HDL) cholesterol rises. The average plasma cholesterol lowering is 25% after diet, with a 40% reduction in the LDL-cholesterol fraction; concurrently, the HDL-cholesterol rises about 8%. These effects have been demonstrated to be maintained for up to 20 years. Currently, PIB is being used in the Program on the Surgical Control of the Hyperlipidemias (POSCH), a randomized controlled clinical trial designed to assess the effects of lipid reduction on mortality and morbidity in a postmyocardial infarction population with arteriographically demonstrated coronary atherosclerosis.",

author = "Henry Buchwald and Laurie Fitch and Varco, {Richard L.}",

year = "1985",

month = dec,

doi = "10.1007/BF01655389",

language = "English (US)",

volume = "9",

pages = "850--859",

journal = "World Journal of Surgery",

issn = "0364-2313",

publisher = "Springer New York",

number = "6",

}

TY - JOUR

T1 - Ileal bypass for hyperlipidemia

AU - Buchwald, Henry

AU - Fitch, Laurie

AU - Varco, Richard L.

PY - 1985/12

Y1 - 1985/12

N2 - Partial ileal bypass (PIB) is a safe, effective, and lasting therapy for the reduction of lipids and lipoproteins in patients with hyperlipidemia. Following PIB, circulating plasma and low-density lipoprotein (LDL) cholesterol fall markedly, while high-density lipoprotein (HDL) cholesterol rises. The average plasma cholesterol lowering is 25% after diet, with a 40% reduction in the LDL-cholesterol fraction; concurrently, the HDL-cholesterol rises about 8%. These effects have been demonstrated to be maintained for up to 20 years. Currently, PIB is being used in the Program on the Surgical Control of the Hyperlipidemias (POSCH), a randomized controlled clinical trial designed to assess the effects of lipid reduction on mortality and morbidity in a postmyocardial infarction population with arteriographically demonstrated coronary atherosclerosis.

AB - Partial ileal bypass (PIB) is a safe, effective, and lasting therapy for the reduction of lipids and lipoproteins in patients with hyperlipidemia. Following PIB, circulating plasma and low-density lipoprotein (LDL) cholesterol fall markedly, while high-density lipoprotein (HDL) cholesterol rises. The average plasma cholesterol lowering is 25% after diet, with a 40% reduction in the LDL-cholesterol fraction; concurrently, the HDL-cholesterol rises about 8%. These effects have been demonstrated to be maintained for up to 20 years. Currently, PIB is being used in the Program on the Surgical Control of the Hyperlipidemias (POSCH), a randomized controlled clinical trial designed to assess the effects of lipid reduction on mortality and morbidity in a postmyocardial infarction population with arteriographically demonstrated coronary atherosclerosis.

UR - http://www.scopus.com/inward/record.url?scp=0022183978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022183978&partnerID=8YFLogxK

U2 - 10.1007/BF01655389

DO - 10.1007/BF01655389

M3 - Article

C2 - 4082609

AN - SCOPUS:0022183978

SN - 0364-2313

VL - 9

SP - 850

EP - 859

JO - World Journal of Surgery

JF - World Journal of Surgery

IS - 6

ER -

Ileal bypass for hyperlipidemia

Abstract

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this